Related Experiment Video
Updated: Mar 30, 2026
13:34
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
10.8K
Proteomic Study to Survey the CIGB-552 Antitumor Effect
Arielis Rodríguez-Ulloa1, Jeovanis Gil1, Yassel Ramos1
1Department of Proteomics, Center for Genetic Engineering and Biotechnology, 10600 Havana, Cuba.
Biomed Research International
|November 18, 2015
Summary
CIGB-552, a cell-penetrating peptide, shows anticancer effects by interacting with proteins involved in cell proliferation and apoptosis. This study reveals its mechanism, including NF-κB pathway inhibition and modulation of cell invasion proteins.
Area of Science:
- Proteomics
- Cancer Biology
- Molecular Pharmacology
Background:
- CIGB-552 is a cell-penetrating peptide with demonstrated in vitro and in vivo antitumor activity.
- Understanding the molecular mechanisms underlying its anticancer effects is crucial for therapeutic development.
Purpose of the Study:
- To elucidate the molecular mechanisms of CIGB-552's antitumor activity.
- To identify proteins and signaling pathways modulated by CIGB-552 in cancer cells.
Main Methods:
- Chemical proteomics was employed to identify CIGB-552 interacting proteins.
- Temporal differential proteomics using iTRAQ quantification identified CIGB-552 modulated proteins.
- Analysis was conducted in cultured cancer cell lines.
Main Results:
- CIGB-552 was found to interact with at least 55 proteins.
- Proteomic analysis identified 72 differentially expressed proteins in response to CIGB-552.
- Key pathways identified include cell proliferation, apoptosis, and NF-κB signaling inhibition.
- Proteins associated with cell invasion were also modulated, suggesting new therapeutic potential.
Conclusions:
- Proteomic approaches provide insights into CIGB-552's antitumor mechanism.
- CIGB-552 modulates critical cellular processes, including proliferation, apoptosis, and invasion.
- The findings support CIGB-552's potential as an anticancer agent and warrant further investigation.
